Targeting YAP in pancreatic ductal adenocarcinoma (PDAC) (Homo sapiens)

From WikiPathways

Revision as of 16:26, 11 November 2024 by Eweitz (Talk | contribs)
Jump to: navigation, search


Description

"Targeting YAP for PDAC therapy. There are several strategies for targeting YAP in PDAC. Statin-mediated inhibition of HMG-CoA reductase in the mevalonate pathway reduces the geranylgeranylation and membrane localization of Rho GTPases, restricting YAP nuclear accumulation and thus its activity. Verteporfin and VGLL4-mimicking peptides disrupt the interaction between YAP and TEAD, inhibiting YAP-induced transcription. Metformin activates AMPK, which inhibits YAP both directly and by activating LATS kinases. BET inhibitors oppose the transcription of YAP-regulated genes. Neratinib increases the phosphorylation of LATS1 and YAP, causing YAP cytosolic accumulation and degradation." Based on Figure F5 in https://pubmed.ncbi.nlm.nih.gov/33408779/. Derived from PFOCR, https://pfocr.wikipathways.org/figures/PMC7778590__thnov11p1753g005.html.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

  1. Mao W, Mai J, Peng H, Wan J, Sun T; ''YAP in pancreatic cancer: oncogenic role and therapeutic strategy.''; Theranostics, 2021 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
135790view18:03, 11 November 2024EweitzOntology Term : 'drug pathway' added !
135789view17:13, 11 November 2024EweitzOntology Term : 'pancreatic ductal cell' added !
135788view17:12, 11 November 2024EweitzOntology Term : 'pancreatic ductal adenocarcinoma' added !
135787view17:02, 11 November 2024EweitzConnect downstream cell phenotypes
135786view16:52, 11 November 2024EweitzAdd literature reference
135785view16:50, 11 November 2024EweitzLabel cell type, organelle
135784view16:38, 11 November 2024EweitzAdd CHEBI identifiers, refine labels
135783view16:26, 11 November 2024EweitzConnect nodes in mevalonate pathway
135782view16:21, 11 November 2024EweitzAdd interactions, groups, complexes
135781view15:54, 11 November 2024EweitzOrganize nodes
135780view15:33, 11 November 2024EweitzNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
AtorvastatinMetaboliteCHEBI:39548 (ChEBI)
CCN1GeneProductENSG00000142871 (Ensembl)
CCN2GeneProductENSG00000118523 (Ensembl)
FluvastatinMetaboliteCHEBI:38561 (ChEBI)
HMG-CoAMetaboliteCHEBI:15467 (ChEBI)
HMGCRGeneProductENSG00000113161 (Ensembl) "HMG-CoA reductase" originally
JQ1Metabolite
LATS1GeneProductENSG00000131023 (Ensembl)
LATS2GeneProductENSG00000150457 (Ensembl)
LovastatinMetaboliteCHEBI:40303 (ChEBI)
MOB1AGeneProductENSG00000114978 (Ensembl)
MetforminMetaboliteCHEBI:6801 (ChEBI)
Mevalonate pathwayPathway
Mevalonic acidMetaboliteCHEBI:25351 (ChEBI)
NeratinibMetaboliteCHEBI:61397 (ChEBI)
PRKAA1GeneProductENSG00000132356 (Ensembl)
PRKAA2GeneProductENSG00000162409 (Ensembl)
PRKAB1GeneProductENSG00000111725 (Ensembl)
PRKAB2GeneProductENSG00000131791 (Ensembl)
PRKAG1GeneProductENSG00000181929 (Ensembl)
PRKAG2GeneProductENSG00000106617 (Ensembl)
PRKAG3GeneProductENSG00000115592 (Ensembl)
PitavastatinMetaboliteCHEBI:32020 (ChEBI)
PravastatinMetaboliteCHEBI:63618 (ChEBI)
RHOAGeneProductENSG00000067560 (Ensembl)
RHOBGeneProductENSG00000143878 (Ensembl)
RHOCGeneProductENSG00000155366 (Ensembl)
RHODGeneProductENSG00000173156 (Ensembl)
RHOGeneProductENSG00000163914 (Ensembl)
RosuvastatinMetaboliteCHEBI:38545 (ChEBI)
SAV1GeneProductENSG00000151748 (Ensembl)
STK3GeneProductENSG00000104375 (Ensembl)
STK4GeneProductENSG00000101109 (Ensembl)
SimvastatinMetaboliteCHEBI:9150 (ChEBI)
TEAD1GeneProductENSG00000187079 (Ensembl)
TEAD2GeneProductENSG00000074219 (Ensembl)
TEAD3GeneProductENSG00000007866 (Ensembl)
TEAD4GeneProductENSG00000197905 (Ensembl)
VGLL4-mimicking peptidesMetabolite
VerteporfinMetaboliteCHEBI:32293 (ChEBI)
YAP1GeneProductENSG00000137693 (Ensembl)

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP5495"
Personal tools